Home > Publications Database > Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome. > print

001     272724
005     20241020000057.0
024 7 _ |a 10.1158/1078-0432.CCR-24-1563
|2 doi
024 7 _ |a pmid:39150564
|2 pmid
024 7 _ |a pmc:PMC11474166
|2 pmc
024 7 _ |a 1078-0432
|2 ISSN
024 7 _ |a 1557-3265
|2 ISSN
024 7 _ |a altmetric:166414762
|2 altmetric
037 _ _ |a DZNE-2024-01226
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Bartos, Laura M
|0 0009-0007-6158-319X
|b 0
245 _ _ |a Remote Neuroinflammation in Newly Diagnosed Glioblastoma Correlates with Unfavorable Clinical Outcome.
260 _ _ |a Philadelphia, Pa. [u.a.]
|c 2024
|b AACR
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1729173420_2185
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Current therapy strategies still provide only limited success in the treatment of glioblastoma, the most frequent primary brain tumor in adults. In addition to the characterization of the tumor microenvironment, global changes in the brain of patients with glioblastoma have been described. However, the impact and molecular signature of neuroinflammation distant of the primary tumor site have not yet been thoroughly elucidated.We performed translocator protein (TSPO)-PET in patients with newly diagnosed glioblastoma (n = 41), astrocytoma WHO grade 2 (n = 7), and healthy controls (n = 20) and compared TSPO-PET signals of the non-lesion (i.e., contralateral) hemisphere. Back-translation into syngeneic SB28 glioblastoma mice was used to characterize Pet alterations on a cellular level. Ultimately, multiplex gene expression analyses served to profile immune cells in remote brain.Our study revealed elevated TSPO-PET signals in contralateral hemispheres of patients with newly diagnosed glioblastoma compared to healthy controls. Contralateral TSPO was associated with persisting epileptic seizures and shorter overall survival independent of the tumor phenotype. Back-translation into syngeneic glioblastoma mice pinpointed myeloid cells as the predominant source of contralateral TSPO-PET signal increases and identified a complex immune signature characterized by myeloid cell activation and immunosuppression in distant brain regions.Neuroinflammation within the contralateral hemisphere can be detected with TSPO-PET imaging and associates with poor outcome in patients with newly diagnosed glioblastoma. The molecular signature of remote neuroinflammation promotes the evaluation of immunomodulatory strategies in patients with detrimental whole brain inflammation as reflected by high TSPO expression.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Receptors, GABA
|2 NLM Chemicals
650 _ 7 |a TSPO protein, human
|2 NLM Chemicals
650 _ 2 |a Glioblastoma: pathology
|2 MeSH
650 _ 2 |a Glioblastoma: genetics
|2 MeSH
650 _ 2 |a Glioblastoma: metabolism
|2 MeSH
650 _ 2 |a Glioblastoma: diagnosis
|2 MeSH
650 _ 2 |a Glioblastoma: mortality
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Receptors, GABA: metabolism
|2 MeSH
650 _ 2 |a Receptors, GABA: genetics
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Brain Neoplasms: pathology
|2 MeSH
650 _ 2 |a Brain Neoplasms: genetics
|2 MeSH
650 _ 2 |a Brain Neoplasms: metabolism
|2 MeSH
650 _ 2 |a Brain Neoplasms: diagnosis
|2 MeSH
650 _ 2 |a Neuroinflammatory Diseases: pathology
|2 MeSH
650 _ 2 |a Neuroinflammatory Diseases: etiology
|2 MeSH
650 _ 2 |a Neuroinflammatory Diseases: diagnosis
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Positron-Emission Tomography: methods
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Prognosis
|2 MeSH
650 _ 2 |a Tumor Microenvironment: immunology
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
700 1 _ |a Quach, Stefanie
|0 0000-0003-2914-3649
|b 1
700 1 _ |a Zenatti, Valerio
|0 P:(DE-2719)9002392
|b 2
|u dzne
700 1 _ |a Kirchleitner, Sabrina V
|0 0000-0001-6864-3369
|b 3
700 1 _ |a Blobner, Jens
|0 0000-0002-8539-8745
|b 4
700 1 _ |a Wind, Karin
|0 P:(DE-2719)9001653
|b 5
|u dzne
700 1 _ |a Kolabas, Zeynep Ilgin
|0 0000-0002-0672-681X
|b 6
700 1 _ |a Ulukaya, Selin
|0 0009-0000-3035-3155
|b 7
700 1 _ |a Holzgreve, Adrien
|0 0000-0002-9566-8438
|b 8
700 1 _ |a Ruf, Viktoria C
|0 0000-0002-3876-8854
|b 9
700 1 _ |a Kunze, Lea
|0 P:(DE-2719)9002311
|b 10
|u dzne
700 1 _ |a Kunte, Sebastian T
|0 0009-0007-3543-5329
|b 11
700 1 _ |a Hoermann, Leonie
|0 0009-0006-9074-3474
|b 12
700 1 _ |a Härtel, Marlies
|0 0009-0007-3195-0980
|b 13
700 1 _ |a Park, Ha Eun
|0 0009-0002-1872-128X
|b 14
700 1 _ |a Groß, Mattes
|0 0009-0001-7729-2182
|b 15
700 1 _ |a Franzmeier, Nicolai
|0 0000-0001-9736-2283
|b 16
700 1 _ |a Zatcepin, Artem
|0 P:(DE-2719)9001654
|b 17
700 1 _ |a Zounek, Adrian
|0 0000-0001-8765-1276
|b 18
700 1 _ |a Kaiser, Lena
|0 0000-0002-2084-5858
|b 19
700 1 _ |a Riemenschneider, Markus J
|0 0000-0002-3742-2982
|b 20
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 21
700 1 _ |a Rauchmann, Boris Stephan
|0 P:(DE-2719)9001808
|b 22
|u dzne
700 1 _ |a Stöcklein, Sophia
|0 0000-0003-0325-4674
|b 23
700 1 _ |a Ziegler, Sibylle
|0 0000-0002-5321-4817
|b 24
700 1 _ |a Herms, Jochen
|0 P:(DE-2719)2810441
|b 25
|u dzne
700 1 _ |a Ertürk, Ali
|0 0000-0001-5163-5100
|b 26
700 1 _ |a Tonn, Joerg C
|0 0009-0004-1756-423X
|b 27
700 1 _ |a Thon, Niklas
|0 0000-0003-0011-5281
|b 28
700 1 _ |a von Baumgarten, Louisa
|0 0000-0002-6634-0927
|b 29
700 1 _ |a Prestel, Matthias
|0 P:(DE-2719)9001400
|b 30
|u dzne
700 1 _ |a Tahirovic, Sabina
|0 P:(DE-2719)2442036
|b 31
700 1 _ |a Albert, Nathalie L
|0 0000-0003-0953-7624
|b 32
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 33
|e Last author
773 _ _ |a 10.1158/1078-0432.CCR-24-1563
|g Vol. 30, no. 20, p. 4618 - 4634
|0 PERI:(DE-600)2036787-9
|n 20
|p 4618 - 4634
|t Clinical cancer research
|v 30
|y 2024
|x 1078-0432
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/272724/files/DZNE-2024-01226.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/272724/files/DZNE-2024-01226.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:272724
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9002392
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 5
|6 P:(DE-2719)9001653
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 10
|6 P:(DE-2719)9002311
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)9001654
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)2812234
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 22
|6 P:(DE-2719)9001808
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)2810441
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)9001400
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)2442036
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 33
|6 P:(DE-2719)9001539
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-25
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN CANCER RES : 2022
|d 2023-08-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-25
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b CLIN CANCER RES : 2022
|d 2023-08-25
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1140003
|k AG Tahirovic
|l Juvenile Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)5000022
|k AG Dichgans
|l Vascular Cognitive Impairment & Post-Stroke Dementia
|x 2
920 1 _ |0 I:(DE-2719)1110001
|k AG Herms
|l Translational Brain Research
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a I:(DE-2719)1140003
980 _ _ |a I:(DE-2719)5000022
980 _ _ |a I:(DE-2719)1110001
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21